Eli Lilly surpassed quarterly earnings estimates and raised its 2026 revenue outlook, driven by surging sales of its Zepbound and Mounjaro drugs.
Key facts
- Eli Lilly topped quarterly estimates, according to CNBC.
- The company raised its full-year 2026 outlook.
- 2026 revenue is now expected between $85 billion and $87 billion.
- Previous guidance was $82 billion to $85 billion.
- Growth was driven by rising Zepbound and Mounjaro sales.
Eli Lilly comfortably exceeded quarterly estimates and raised its full-year outlook, buoyed by continued strong demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro, according to CNBC.
The pharmaceutical company now expects its 2026 revenue to land between $85 billion and $87 billion. That marks an increase from its previous guidance, which had projected revenue of $82 billion to $85 billion.
The upgraded outlook reflects the ongoing momentum behind Lilly’s two headline products. Zepbound and Mounjaro, both part of the fast-growing market for GLP-1 medications, have been central to the company’s recent performance.
The higher revenue range signals confidence from the company in sustained demand for the two drugs through the remainder of the year, as reported by CNBC.
The results underscore how deeply the surge in weight-loss and diabetes treatments has reshaped Eli Lilly’s financial trajectory, with the company continuing to lift expectations as sales climb.
Why it matters
Eli Lilly's raised guidance signals the continued strength of the booming market for weight-loss and diabetes drugs, which has become a major driver of the company's growth. For patients, investors and the wider healthcare sector, the results reflect how central GLP-1 medications like Zepbound and Mounjaro have become to the industry.
Frequently asked questions
What is Eli Lilly's new 2026 revenue guidance?
Eli Lilly now expects 2026 revenue between $85 billion and $87 billion, up from its previous guidance of $82 billion to $85 billion, according to CNBC.
Which products drove Eli Lilly's growth?
Sales of the weight-loss drug Zepbound and the diabetes treatment Mounjaro surged, driving the company's stronger-than-expected results, according to CNBC.
Did Eli Lilly beat quarterly estimates?
Yes. CNBC reported that Eli Lilly easily topped quarterly estimates.